



MRI of the renal arteries

David A. Bluemke, M.D., Ph.D., FAHA

Director, Radiology and Imaging Sciences

NIH Clinical Center

Senior Investigator, NHLBI, NIDDK

Bethesda, Maryland, USA

Disclosures

Off-label use: gadolinium enhanced
MRI of the blood
vessels

Screening for Renal Artery Stenosis:

- low morbidity - no contrast reactions
- rapid exam - 15 minutes
- low nephrotoxicity compared to iodine agents



3D Gadolinium Renal MRA

| <u>Study</u> | <u>Yr</u> | <u># arteries</u> | <u>Sens.</u> | <u>Spec.</u> |
|--------------|-----------|-------------------|--------------|--------------|
| Korst et al. | '00 | 92 | 100% | 85% |
| De Cobelli | '00 | 103 | 94% | 93% |
| Thornton | '99 | 87 | 100% | 98% |
| Thornton | '99 | 138 | 88% | 92% |
| Hany | '98 | 235 | 93% | 90% |
| Bakker | '98 | 121 | 97% | 92% |
| De Cobelli | '97 | 105 | 100% | 97% |
| Postma | '97 | 74 | 100% | 96% |
| Hany | '97 | 78 | 93% | 98% |

Fluoroscopic MRA trigger




Fluoroscopic MRA trigger



MRA: Venous phase

3d VIBE, SPGR



MRA: 2nd run

MRA - Aorta



- 3D acquisition,
2mm slice
thickness
- 0.15 mmol/kg
gad @ 2ml/sec
- Automated
timing bolus
- 15 sec breath-
hold



Renal MRA ?



Renal MRA



Renal MRA: data analysis


- MIP image
- most common “data reduction” method




MRA - reformat



axial



coronal



sagittal

MRA - reformat




MRA - reformat



3T Renal MRA




3T Renal MRA





to VOI
FOV 26.0 cm
I = 571 I = 271



MRA - reformat



Eccentric plaque - MIP pitfall




Volume Rendering

- retains “3d” information




MR angiogram: accurate/ rapid anatomy





Maximum intensity projection and surface displays

Aorto-enteric fistula repair, aneurysm





Renal MRA: Aneurysm



Dynamic MRA (TREAT)

MRA - variant anatomy




MRA - document variant anatomy

- Early arterial branching




MRA: variant anatomy




Pitfall



Pitfall - susceptibility





Pitfall - stent





Pitfall: adenoma



Pitfall: adenoma



Pitfall: adenoma




Renal MRA: size matters

- 3D renal size
- Is there sufficient renal mass for revascularization?
- > 1 cm L/R renal size difference




Renal Artery MRA: disadvantages?

- tendency to overestimate (calcification, turbulence)



Female, long standing hypertension




“Hypertension”


Fibromuscular
dysplasia



Fibromuscular dysplasia



MRA



CA


Pressure gradient

- By convention, 50% stenosis “physiologically significant”
- Experimentally, 70-80% required for a pressure gradient








MRA: Phase contrast

- Improved specificity for stenosis detection
- *After* 3D MRA




Eccentric plaque - MIP pitfall





Phase contrast

Renal MRA: phase contrast



Mild stenosis




phase contrast

3T Renal MRA: phase contrast



3T Renal abnormality




Renal transplant

Increasing creatinine:

- Vascular insufficiency?
- Rejection?
- Concern for NSF



Renal transplant- multiple reformations



Targeted MIP




3D volume



Oblique MIP - early branching

Renal transplant

“Normal”
anastomotic
narrowing



Associations with NSF

- Prior gadolinium administration
- Severe renal failure, dialysis

| Stage | GFR | Description |
|-------|-------|--|
| 1 | 90+ | Normal kidney function but urine or other abnormalities point to kidney disease |
| 2 | 60-89 | Mildly reduced kidney function, urine or other abnormalities point to kidney disease |
| 3 | 30-59 | Moderately reduced kidney function |


Associations with NSF

- Prior gadolinium administration
- Severe renal failure, dialysis
- Pro-inflammatory events
 - surgery
 - infection
 - trauma

Gadolinium MRA: options in at risk patients


1. Noncontrast time of flight MRA
2. 3T MRA: 50% reduction of contrast dose
3. Contrast agent with increased relaxivity (Multihance); allows dose reduction
4. both (2) and (3)

Gadolinium MRA: Time of Flight



Steady State Free Precession (SSFP) TrueFISP, NATIVE


- Blood is imaged as a fluid (long $T2^*$ time) using a balanced GRE sequence
- ECG and navigator gated



Steady State Free Precession (SSFP): TrueFISP, NATIVE




Steady State Free Precession (SSFP): TrueFISP, NATIVE




Multihance, 3T







0.08 mmol/kg




H






Multihance, 3T



5 cc

Renal MRA (3T): with 3d T1



Acknowledgements

- Christine Lorenz, PhD, Steve Shea, PhD, Siemens
- Paul Finn, MD, UCLA
- Gerhard Laub, PhD, Siemens

Thank you